Abstract: Despite the lack of evidence, augmenting pelvic organ prolapse surgery with biologic graft or synthetic mesh is increasing. The objective of this review is to examine the available grafts and meshes and discuss the current data addressing the use of these implants in correction of apical, anterior, and posterior prolapse. Most of the studies are retrospective with few randomized controlled trials. There is level I evidence suggesting that repair of apical prolapse with abdominal sacral colpopexy using synthetic mesh results in improved outcomes. However, most of the data concerning graft or mesh incorporation in anterior or posterior repairs do not support augmentation with prosthesis.
Introduction
Pelvic organ prolapse is a common phenomenon in women. Eleven percent of the female population will undergo surgery for prolapse in their lifetime. 1 Approximately 30% of these women will need a repeat operation for recurrent prolapse within 4 years of the original surgery. Presently, there is no standard surgical approach to patients who suffer from recurrent prolapse; however, in an attempt to improve outcome, some investigators have recommended the use of synthetic or biologic graft material or prosthesis in these patients.
The concept of using mesh or grafts to improve native tissue in hernia repairs is not novel. Prosthetic devices for abdominal hernia repairs have been found as early as ancient Egypt. What is new is the rapid expansion and marketing of new synthetic and biologic mesh materials. Unlike medications, approval for prosthetic devices by the Center for Devices and Radiologic Health is less strictly regulated; the main prerequisite is for new products to demonstrate ''equivalency'' to existing devices. 2 Common indications for graft augmentation in reconstructive pelvic surgery include nonexistent or suboptimal autologous tissue, connective tissue disorder, unavoidable stress on the repair (chronic lifting, chronic obstructive pulmonary disease, chronic straining to defecate, obesity), the need to bridge a space, concern about vaginal length or caliber, and denervated pelvic floor. At a recent convention of the International Urogynecological Association, some of the accepted contraindications included host conditions that may compromise the vascular supply to the pelvic floor such as a history of pelvic radiation, poorly controlled diabetes, severe vaginal atrophy, and factors that may predispose the patient to infections such as systemic steroid use, active vaginal infection, and being a heavy smoker. 3 These guidelines are based on expert opinions as there is currently no literature that specifically compares the impact of patient factors on pelvic reconstruction with or without graft augmentation. In most cases, the decision to use graft augmentation is based on experience and expertise rather than concrete data.
Although there is good evidence to support the use of synthetic material in the abdominal repair of prolapse (abdominal sacral colpopexy) and in suburethral sling procedures such as the tension-free vaginal tape (TVT), the use of synthetic or biologic implants in transvaginal reconstructive procedures is less clear. There exist numerous retrospective and nonrandomized studies that have examined the use of different implants in the vaginal repair of anterior or posterior compartment prolapse with very few randomized surgical trials and no trial directly comparing different biologic or synthetic implants. In this review, we will first consider properties of the ideal graft material and host tissue responses to graft implantation. We will then summarize the evidence on using different grafts and meshes in pelvic reconstructive surgery.
Properties of the Ideal Implant
The ideal graft/mesh would be chemically and physically inert, noncarcinogenic, mechanically strong, sterile, not physically modified by body tissue, readily available, inexpensive, and have minimal risk of infection and rejection. In prolapse surgery, the optimal implant, once healed, would restore normal anatomy and function to the vagina and the surrounding pelvic organs, and be more durable or equally durable to autologous tissue. The ideal graft/mesh would be biocompatible and, if biodegradable, persist long enough for incorporation of the surrounding native tissue. It should resist mechanical stress and shrinkage, be pliable and easily manipulated during surgery, and, once implanted, not result in adhesion formation at visceral surfaces. Currently, there are no biologic or synthetic implants that meet all the above criteria.
Biologic Properties of Host Tissue
Although the exact pathophysiology of prolapse is unknown, altered metabolism of pelvic floor connective tissue as a potential contributor has been demonstrated and is widely accepted. As most of the commonly described techniques in abdominal and vaginal prolapse surgery involve correcting or compensating for potential defects in pelvic floor connective tissue, we will review the role of connective tissue in the pelvic floor and potential interactions between host tissue and implanted materials before discussing properties of various biologic grafts and synthetic meshes.
Pelvic floor connective tissue is comprised of fibroblasts, smooth muscle, blood vessels, and supportive structures such as collagen, elastin, and laminin. Whereas elastin and laminin are glycoproteins that are thought to play a role in a tissue's ability to stretch, the tensile strength of a biologic tissue is in large part due to the collagen content. The 2 collagen types that predominate in pelvic floor connective tissue are type I: large fibers that prevail in tissues with high tensile strength such as rectus fascia and ligaments, and type III: smaller fibers that are found in distensible tissues such as blood vessels. Recently, it has been demonstrated that type III collagen is the major collagen found in the vagina, arcus tendineous fascia pelvis, and uterosacral ligament. [4] [5] [6] In general, after reconstructive surgery, wound healing and restoration of tissue strength is a result of fibrous protein synthesis and remodeling with collagen playing a central role. Immature fibroblasts synthesize and secrete collagen and proteoglycans within 24 hours of surgery. During the first 2 weeks after reparative surgery, type III collagen is the principal type found. With maturation of scar tissue, a stronger type I collagen will often replace type III collagen. In contrast, there is less synthesis and remodeling of elastin. Scar tissue resulting from wound healing after surgical repair is never as strong as the original tissue it replaces.
For the scope of this review, it is also important to summarize host tissue reactions to implanted materials. The ideal graft/mesh should be biocompatible, which is defined as the capacity of a material to cause a favorable reaction in a living system thus resulting in augmenting or replacing a natural function. In 1973, Williams described 4 types of soft tissue responses that can result from the implantation of specific synthetic materials: (1) relatively inert implants can cause a minimal foreign body response, which is similar to normal wound healing, and results in fibrosis around the mesh, (2) the chemical properties of the implant can cause a chemical response, such as hydrolysis, which results from interactions between host inflammatory mediators and the chemical characteristic of the mesh, (3) implants can also induce a physical response in the host with inflammatory cells and giant cells eventually leading to ingrowth of host tissues into the mesh, (4) implantation of mesh under certain conditions can result in necrosis caused by in situ exothermic polymerization by the host. 7 In addition, the 4 histologic stages of host reaction to biologic graft implantation described by Kaupp 
Properties of Biologic Graft
Biologic implants include autologous grafts (tissue harvested from the patient), allografts (tissue procured from a source other than the recipient but from the same species), and xenografts (tissue procured from a species different from the recipient) (Fig. 1) . Commonly used autologous grafts in prolapse surgery include rectus fascia and fascia lata (deep fascia around the muscles of the thigh). Allografts include cadaveric dermis and cadaveric fascia lata. Xenografts include collagen matrix laminates made from porcine dermis (PD) and small intestine submucosa and also bovine pericardium and dermis. Besides autologous grafts, which usually do not require treatment after harvest, the various biologic grafts are processed differently depending upon the specific types of tissue and also the specific company that manufactures the grafts (Table 1) . The different abbreviations used in this review for biologic tissues and the different processing techniques are listed in Table 2 .
In general, allografts and xenografts share the advantage of avoiding potential morbidities associated with autologous graft harvest; however, this advantage must be weighed against the potential risk for tissue rejection. However, the risk for tissue rejection should be low as allografts and xenografts are designed to provide a scaffold of acellular material to facilitate the infiltration and subsequent replacement of graft tissue with regenerated functional host tissue. Of late, xenografts have gained popularity in pelvic prolapse surgery because of concerns regarding the availability of allograft tissue and the risk of virus and prion transmission discussed below. Additionally, xenografts, such as PD, have been used in other surgical disciplines such as cardiothoracic and general surgery for decades, and have been found to be safe and efficacious.
Although tissue processing is important as different methods can vary the effects on the biologic and biomechanical properties of the graft, there is no consensus on which protocol should be implemented to produce the ideal biomaterial. Before allograft harvest, the donors are serologically screened for transmissible infectious organisms such as hepatitis B and C, HIV, and HTLV-1 along with a medical and social history. The allografts are harvested using aseptic technique and microbiologic cultures are also obtained. After harvest, the grafts undergo sterilization, which can occur by various techniques such as freeze-drying, solvent dehydration, or g-irradiation. A recent investigation by Grimes et al 9 emphasized that little is known regarding the affects of different sterilization techniques on the structure, mechanical strength, and biocompatibility of biomaterials. The authors showed that all currently employed sterilization methods of porcine small intestinal submucosa (SIS) with ethylene oxide (solvent dehydration), g-irradiation, and e-beam irradiation resulted in an increase in the rate of sample degradation. There is also an initial increase in metabolic activity and protein production by the host. Therefore, the authors hypothesize that although the sterilization techniques resulted in increased sample degradation, this degradation process resulted in the initial increased release of certain growth factors, which may ultimately affect the biocompatibility of the grafts.
Furthermore, as allografts and xenografts are harvested from the extracellular tissue matrix consisting mainly of proteins, collagen, elastin, and various growth factors, these grafts are essentially acellular and should also be devoid of any genetic material or cell surface proteins. Theoretically, acellularity renders the graft less capable of eliciting an inflammatory response by the host (nonimmunogenic) thus decreasing the risk of rejection and erosion after implantation. However, there are published data that refute the acellularity and nonimmunogenicity of various biomaterials. Zheng et al 10 recently showed the presence of porcine DNA in SIS implants for tendon repair. Fitzgerald Alloderm, LifeCell, Woodlands, TX) contained intact genetic material. This is of particular concern because of the theoretical risk of prion and HIV transmission during allograft implantation, which is estimated at 1 in 3.5 million and 1 in 8 million, respectively. 14,15 Despite the above findings and theoretic concern, there has been no reported case of disease transmission after allograft implantation in prolapse surgery.
In addition to sterilization, biomaterials, especially xenografts, are often Despite the lack of data, delaying reabsorption is thought by many in industry to increase the success of graft augmentation procedures. Types of agents used in the cross-linking process include aldehydes, which are cytotoxic at higher levels, and may also lead to the development of calcifications on the grafts thereby impeding their function. Although investigators have found anticalcification treatments, they also found that grafts implanted after these treatments lead to increased concentrations of gelatinases, which may ultimately escalate the rate of graft degradation thereby nullifying any potential advantage initially conferred by the cross-linking process. 16 Another agent used in cross-linking some PD products is hexamethylene di-isocyanate (HMDI). Animal studies in rats have shown no evidence of mineralization after implantation of HMDI cross-linked porcine dermal graft implantation at 2 years. 17 In conclusion, it is unknown whether cross-linking, despite prolonging a graft's existence, renders it more effective in pelvic surgery; however, aldehyde crosslinked implants should be avoided because of mineralization of the grafts.
Some biologic tissues are also fenestrated to assure porosity resulting in enhanced fibrocollagenous ingrowth and angiogenesis. Fenestrations are also thought to decrease the risk of seroma formation and infection after implantation. Therefore, some companies recommend fenestration/perforation of the graft before surgical implantation.
In addition to the differing biologic properties of various grafts, the biomechanical characteristics of grafts will also depend on the origin of the tissue and host recipient, and also the specific processing method. Choe et al 18 )] used in sling procedures and evaluated full strip slings versus patch suture slings. They found that overall the tensile strengths for the full strip slings were significantly greater than for the patch suture slings. Specifically, in full strip slings, both types of cadaver allografts (FD-CDA and FD/IR-CFL) had the strongest tensile strength, followed by the synthetic slings, and autologous tissues (P<0.05). In patch slings, the synthetics (Gore-tex and polypropylene mesh) and dermal tissues (autologous dermis and FD-CDA) had the highest tensile strength followed by FD/IR-CFL, ARF, and vaginal mucosa (P<0.05). Lemer et al 19 compared the mechanical properties of ARF from patients presenting with stress urinary incontinence, SD/IR-CFL, (Tutoplast, Mentor, Santa Barbara, CA), FD-CFL (North California Transplant Bank, San Rafael, CA), and FD-CDA (Alloderm, LifeCell, Woodlands, TX) and found that ARF, SD/IR-CFL and FD-CDA had statistically similar maximum load to failure compared with FD-CFL, which had a statistically decreased maximum load to failure compared with the other 3 grafts.
One limitation of the above studies is that the grafts underwent mechanical testing in their native state without initial implantation in patients. Therefore, they were not subjected to any potential alteration or remodeling by the host, which could impact on their biomechanical properties. Fokaefs et al 20 showed in a rabbit model that rabbit autologous rectus fascia (ARF), either as a free flap or pedicle flap, shrank by 37% in length and 63% in width and had reductions in tensile strength up to 53% after implantation for 12 weeks. Furthermore, there was neovascularization with minimal inflammation and reactive fibrosis that was found only along the permanent sutures used to secure the graft. Walter et al 21 also demonstrated in a rabbit model that there is a 90% decrease in tensile strength of FD/IR-CFL after implantation for 12 weeks. In the same study, the authors also showed a wide variation in baseline tensile strength amongst grafts from different lots and grafts from the same lot taken from different areas. It is unclear if this has any clinical significance as it is unclear what tensile strength is ideally required for prolapse surgery. In another study by the above authors using the same animal model to examine cadaveric dermal allograft (CDA) (Repliform, Boston Scientific, Natick, MA), fenestrated cross-linked acellular porcine dermal matrix (HMDI/ IR/F-PD) (Pelvisoft, CR Bard, Murray Hill, NJ), porcine collagen-coated monofilament polypropylene mesh (HMDI/ IR-PD) (Pelvitex, CR Bard, Murray Hill, NJ), and autologous rabbit fascia, the authors found a decrease in the ultimate strength and elasticity of all the grafts 6 and 12 weeks after implantation. 22 Furthermore, there was minimal neovascularization in all the grafts with minimal inflammation in the autologous fascia and Pelvitex implants and moderate inflammation in the other grafts. There was also minimal collagen ingrowth in the repliform and Pelvisoft grafts with moderate collagen ingrowth in the Pelvitex and autologous fascia implants with encapsulation of the Pelvitex implant.
In another rabbit model, 6 materials: 2 types of cadaveric fascia lata (SD/IR-CFL, Tutoplast, Mentor, Santa Barbara, CA, and FD/Allowash-CFL, LifeNet, Virginia Beach, VA), porcine small intestine submucosa (SD/FD-SIS, Stratasis, Cook Urological, Spencer, IN), PD (Derm Matrix, Carbon Medical Technologies, Saint Paul, MN), polyproylene mesh (SPARC, American Medical Systems, Minnetonka, MN), and rabbit ARF were investigated for tensile strength, stiffness, shrinkage, and distortion after implantation for 12 weeks in rectus fascia. 23 They showed that both types of human cadaveric fascia and porcine xenografts showed a marked decrease (60% to 89%) in tensile strength and stiffness from baseline. Polypropylene mesh and ARF did not differ in tensile strength from baseline. Direct comparison of TVT polypropylene sling and CFL sling in an in vivo rat model showed that TVT mesh has a greater break load and maximum average load than CFL after implantation. 24 In summary, there exist wide variations in materials used for biologic graft augmentation and methods of processing these grafts. The clinical impact of the different processing techniques is unclear. It is difficult to compare different studies because of the diversity of graft materials and different processing methods and also the different animal models used and the different sites of implantation. In general, it would seem that dermal allografts (CDA) or solvent-dehydrated fascia lata (SD-CFL) and synthetic mesh in the native state (without implantation) have equal or higher tensile strength compared with autologous fascia. In some studies, it was found that grafts that have been FD have lower tensile strength than similar grafts that have been solvent-dehydrated (SD). After implantation, autologous fascia and synthetic mesh seem to retain more of their tensile strength than allograft or xenograft. Histologically, this is coupled with increased inflammation and decreased collagen ingrowth in the latter grafts. It is unclear if these findings can be extrapolated to explain the differing clinical observations resulting from the use of various biologic grafts in human trials.
Properties of Synthetic Mesh
Synthetic material comes in many different forms with distinct characteristics, targeted for specific functions. Significant advantages of synthetic mesh include the lack of potential infectious disease transmission and high tensile strength (more than 50 N). Also, synthetic mesh is readily available, cost-effective, and does not require harvesting, therefore decreasing operative risks.
Synthetic mesh can be absorbable or nonabsorbable. Absorbable implants are desirable because they promote postoperative fibroblast activity, are not threatened by infection, do not undergo rejection, and are not known to be harmful to viscera. Once absorbable synthetics are implanted, macrophage activation leads to mesh absorption and subsequent recycling of byproducts into new collagen fibers. 25 One disadvantage to absorbable implants is that the resultant scar tissue is not as strong as the reinforced tissue as evidenced in animal studies 26 and this loss of tensile strength may make them less desirable for reconstructive pelvic surgery. The commercially available absorbable synthetic mesh implants are polyglycolic acid (Dexon, Davis and Geck, American Cyanamid, Danbury, CT) and polyglactin 910 (Vicryl, Ethicon, Somerville, NJ). Although both products are considered absorbable, their properties are distinct. Polyglactin 910 starts to hydrolyze during the third week after implantation and loses the majority of its mechanical value after 30 days, whereas polyglycolic acid requires 90 days for absorption.
Synthetic meshes can be further characterized as macroporous or microporous. Pore size greater than 75 mm is considered macroporous, whereas that less than 10 mm is considered microporous. Pore size and porosity determine which cells (macrophages versus bacteria) can enter mesh and therefore are considered the most important synthetic mesh characteristics.
Although most bacteria measure less than 1 mm in diameter and granulocytes and macrophages measure greater than 10 mm in diameter, 75 mm is a significant measurement, as this has been reported as the necessary pore size to allow entry of fibroblasts, macrophages, blood vessels, and collagen fibers. 27, 28 Because of the increased permeability, the best mechanical anchorage with collagen infiltration is noted with pore sizes between 50 and 200 mm. Therefore, pore size plays an important role in mesh infection prevention and fibrous ingrowth of surrounding tissues. Pore size also affects flexural rigidity. Larger pore size translates to decreased flexural rigidity. For example, although both Marlex and prolene are monofilament synthetic meshes, prolene is more flexible owing to its larger pore size and Marlex, with a smaller pore size, reportedly has the highest flexural rigidity.
Synthetic mesh implants are also classified as monofilament or multifilament (Fig. 2) . Multifilament synthetic material has interstices within the filamentous fibers that measure less than 10 mm. These spaces theoretically allow bacteria to enter and replicate but prevent penetration of host immune cells, handicapping the host's ability to combat bacterial colonization. Therefore, some authors have noted this as a theoretic disadvantage of multifilament mesh in comparison with monofilament mesh. 29, 30 Nonabsorbable synthetic mesh has been reclassified as types I to IV with respect to pore size and filamentous nature as described by Amid. 31 Refer to Table 3 for various grafts and associated properties.
K Type I is macroporous (pore size >75 mm) and monofilamentous. K Type II is microporous (pore size <10 mm) in at least 1 of its 3 dimensions.
K Type III is a macroporous material with multifilamentous or microporous components. K Type IV is submicronic (pore size <1 mm). This type of mesh is often associated with type I mesh for adhesion prevention in intraperitoneal implantation and is not currently used in gynecologic surgery.
Type I mesh, on the basis of pore size, theoretically makes the best implant, as its macroporous, monofilament nature promote host defenses and rapid infiltration. The large pore size also makes it more flexible and easier to work with. Type II and III meshes, with smaller pore size result in greater foreign body reaction when compared with type I mesh. For example, erosion rates associated with type II meshes, such as Marlex, Dacron, and Mersilene range from 20% to 30%. 32, 33 Klinge et al 34 further noted that microporous mesh had ongoing perimesh inflammatory reaction at 18 months. Microporous and macroporous multifilament meshes seem to be associated with greater infection rates and poor tissue ingrowth. For example, microporous multifilament mesh such as Gore-tex is associated with a high infection rate and foreign body reaction.
The mechanical properties of the synthetic implant structure depend on the structure of the fabric and the thread. The tensile strength of permanent synthetic mesh is highly variable depending on fiber type, weight to area ratio, and weave. To increase versatility, materials can be structured from monofilament or multifilament fibers, which can be twisted, coated, braided, or doublebraided. Furthermore, implants can have perforations and be molded into various shapes: kidney, umbrella, or a plug. These materials can be woven, knitted, or unwoven. The advantages of woven materials, including plain, twill, and satin are strength and good memory (Fig. 3) , whereas the disadvantages of woven structures are fraying and poor conformity. The advantages of knitted materials, consisting of warp-knit, interlock, and circular knit (Fig. 4) are flexibility, versatility, and high conformity. The unwoven materials are wellabsorbed but have the disadvantages of nonconformity and poor visibility.
Cosson et al 35 known about how various mechanical properties of mesh contribute to the function and longevity of a reparative procedure.
Properties of Composite Mesh
Composite meshes can be synthetic meshes that have 2 distinct surfaces, one of which is a type IV mesh and has pore sizes that are submicronic, designed to prevent adhesions (Table 4) . Composite meshes can also be made of a synthetic mesh with biologic graft components. One such mesh recently introduced in the United States for pelvic reconstructive surgery is a monofilament polypropylene mesh coated with hydrophilic porcine collagen (Pelvitex, C.R. Bard, Covington, GA). The hydrophilic, absorbable coating protects the viscera from risk of adhesion formation during the first 10 to 14 days after surgery when inflammatory processes peak. Although there are no published manuscripts on the use of this mesh in pelvic floor procedures, adhesion formation has been found to be minimal in abdominal hernia repair. 36 This mesh is also a lightweight monofilament polypropylene thought to maintain strength, increase flexibility, and decrease mesh load on the tissues. Lighter weight and decreased load of mesh may decrease erosion.
Clinical Results and Complications in Prolapse Surgery
In general, meshes and grafts are indicated when the host tissue is insufficient for proper repair and in certain situations where the patient is at high risk for surgical failure. Indications for mesh and graft augmentation in anterior 
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Chen et al or posterior vaginal prolapse may include recurrent prolapse, connective tissue disorder, chronic straining or increases in abdominal pressure, concomitant perineal descent, denervation of the pelvic floor, chronic constipation, or surgeon preference. According to the fourth International Consultation for Incontinence Committee for Pelvic Organ Prolapse review, there are insufficient data to make any definitive conclusions with regard to the role of biologic or synthetic prosthetic materials in primary or recurrent prolapse surgery. 37 Because of the paucity of baseline data regarding the efficacy of traditional anterior and posterior vaginal repairs, the efficacy of adding prosthetic materials is difficult to assess. Although there is a suggested theoretical advantage with mesh and graft augmentation, this must be balanced against potential morbidity and cost.
To date, as most of the studies in the literature addressing using biologic graft or synthetic mesh in prolapse surgery are either retrospective or uncontrolled, they are susceptible to various biases and should be interpreted with caution. Many investigations are industry-sponsored, thus at further risk for bias. There is also a lack of studies comparing the cost of procedures involving tissue implantation with traditional surgical procedures. In this section, we will review studies involving different biologic grafts (autograft, allograft, and xenograft) and synthetic mesh (absorbable and permanent) used in apical prolapse surgery and also in vaginal reconstructive surgery. There are many inherent difficulties with making valid comparisons between studies or clear statements regarding the efficacy of certain grafts or meshes. Firstly, there exist multiple variations of standard procedures in prolapse surgery. It is often unclear whether these small or large variations in techniques have an impact on anatomic or functional outcome. Patients in these studies often undergo other concomitant procedures so that it is difficult to make any definitive statements regarding the efficacy of a specific graft or mesh in isolation without taking into account the specific way the implant was used and the additional procedures that were performed. There exist multiple variations in processing of different graft materials, which may or may not affect the clinical performance of the grafts; clinical findings from a specific graft from one company may not be applicable to the same graft material from another company. Finally, it is often difficult to compare the success rates in different trials owing to the lack of a consensus on the definition of anatomic cure and a deficiency of validated questionnaire usage to document functional outcomes.
APICAL PROLAPSE
There is consistent and reproducible evidence to support abdominal sacral colpopexy as a reliable and effective method of correcting vaginal vault prolapse. 38 The technique of abdominal sacral colpopexy generally involves attaching an intervening piece of biologic graft or synthetic mesh between the vaginal apex and sacrum (Tables 5, 6 ). These tables reflect the evidence for the use of graft or mesh solely in abdominal sacral colpopexy.
BIOLOGIC GRAFT
Besides early reports in the 1970s of using autologous fascia for colposuspension, there is currently only 1 study in the *Anatomic cure was defined as all anterior POP-Q points above the hymen and POP-Q points C and D at least half-way above the hymen. wAnatomic cure was defined as the absolute value of POP-Q point C no more than 2 cm less the total vaginal length. 39 Pelvic Organ Prolapse Quantification System (POP-Q) 47 scores improved and remained at stage II or better in all patients postoperatively. There was no morbidity associated with the tissue harvest.
The literature dealing with allografts in sacral colpopexy is also limited. In 1 series of 53 patients with median followup interval of 17 months, FD/IR-CFL sacral colpopexy was associated with 83% failure rate. 40 Of note, out of the 16 patients who had failed procedures who chose to undergo another abdominal sacral colpopexy (with synthetic mesh), 13 of these patients had no grossly visible biologic graft at their reoperation. Another study by the same authors addressed the histopathologic appearances of some of the failed FD/ IR-CFL sacral colpopexy and suburethral sling specimens. They found wide variations ranging from organized remodeling of the allograft by host fibroblasts with deposition of connective tissue to noninflammatory scar tissue without organized collagen deposition to an infiltrate of host inflammatory cells. 48 Another recent investigation of 19 patients also using FD/Allowash-CFL (ReadiGRAFT, LifeNet, Virginia Beach, VA) showed a 95% cure rate at the vaginal apex at 1 year. 41 The disparity in the above findings could be secondary to the differences in sacral colpopexy techniques employed by the different institutions, variations in the specific processing of the lyophilized allografts [irradiation (Fitzgerald et al) 40 vs. sterilization and proprietary washing, Allowash (Flynn et al) 41 ], and/or differences in the definition of successful outcome.
In terms of adverse events, Kammerer-Doak et al 49 reported vaginal erosion in 3 of 11 patients (27%) after FD-CFL abdominal sacral colpopexies and in 5 of 22 patients (23%) following FD-CFL suburethral sling procedures. 49 Fifty percent of the patients with vaginal erosion required surgical excision of exposed graft under local anesthesia.
There is currently 1 randomized controlled trial involving 100 patients that compared SD/IR-CFL (Tutoplast, Mentor Corp, Santa Barbara, CA) with polypropylene mesh (Trelex, Boston Scientific, Boston, MA) in abdominal sacral colpopexy and found that 68% of the allograft group compared with 91% of the synthetic mesh group were objectively cured (POP-Q stage I or better) at the 1-year follow-up (P = 0.007). 42 This is similar to a retrospective study that compared sacral colpopexy performed with FD-CFL (Community Tissue Services, Portland, OR) or synthetic mesh, Marlex (CR Bard, Cranston, RI) or Mersilene (Ethicon, Somerville, NJ), in 37 patients (19 synthetic mesh and 18 allograft) and found that 61% of patients in the allograft group had optimal outcome as compared with 89% of the patients in the synthetic mesh group with mean follow-up intervals of 21 and 26 months, respectively (P = 0.06). 43 There were no significant adverse events such as erosions from either group.
Altman et al 44 compared clinical outcomes after abdominal sacral colpopexy with HMDI/IR-PD (Pelvicol, CR Bard, Murray Hill, NJ) versus synthetic meshes, polypropylene and expanded polytetrafluoroethylene (Gore-tex, W. L. Gore & Associates, Phoenix, AZ) and found no statistical differences in the 2 cohorts with respect to anatomic cure, reoperation rates, lower urinary tract or anorectal symptoms and quality of life variables. There were no significant complications associated with either group except that more patients in the xenograft group experienced persistent postoperative fevers (>381C for >3 d). Multiple studies supporting the use of polypropylene mesh for abdominal sacral colpopexy exist. Blanchard et al 46 collected data prospectively on 40 women undergoing abdominal sacral colpopexy with Marlex mesh. They found an objective success rate of 77.5% at a median 25.5 months and no significant mesh-related complications. Others have reported success rates ranging from 91% to 94% with mesh-related complications ranging from 2% to 3.7%. 42, 51 A study by Limb et al 45 supports the use of Mersilene mesh as well. They report abdominal sacral colpopexy with Mersilene mesh in 61 consecutive patients with an objective cure rate at 26 months of 91%, subjective cure rate of 90%, and a complication rate of 15%. 45 Govier et al 52 performed a retrospective study comparing sacral colpopexy using silicone-coated polyester mesh and polypropylene mesh and found significantly higher complications including mesh erosion and mesh infection among the silicone-coated polyester mesh group. 52 Although the objective outcomes for sacral colpopexy with synthetic mesh are favorable, it is necessary to fully understand the risks and possible complications. Visco et al 53 retrospectively analyzed Mersilene mesh erosion rates in 273 women who had undergone sacral colpopexy or sacral colpoperineopexy. Overall risk of erosion was 3.2% for abdominal sacral colpopexy and 4.5% for sacral colpoperineopexy (introducing the graft and sutures abdominally). Erosion increased to 16% if sutures were placed vaginally and attached to an abdominally introduced mesh during sacral colpoperineopexy. If the mesh was introduced vaginally, the erosion rate peaked at 40%. The median times to mesh erosion was 15.6 months for abdominal sacral colpopexy, 12.4 months for sacral colpoperineopexy, 9.0 months for vaginally placed sutures with abdominal sacral colpopexy, and 4.1 months for vaginally placed mesh.
Grafts and Meshes in Prolapse Surgery

SUMMATION
In summary, the literature addressing any type of biologic grafts in abdominal repair of apical prolapse is sparse and inconsistent. Most of the data are retrospective or uncontrolled with low complication rates. However, there is good literature to support the use of nonabsorbable synthetic implants, specifically polypropylene mesh, in abdominal sacral colpopexy with low erosion rates. In addition, there is 1 level I study that demonstrated higher anatomic cure rates at 1 year with synthetic mesh (polypropylene) compared with allograft (SD/IR-CFL). 42 However, it remains unclear whether one specific biologic or synthetic mesh is better than another.
ANTERIOR PROLAPSE
Surgeons have turned to biologic graft and synthetic mesh incorporation at the time of anterior repair in an attempt to improve outcomes. This practice continues to increase despite the paucity of supportive data.
BIOLOGIC GRAFT
Biologic grafts have been used to both augment anterior repairs and vaginal paravaginal repairs ( augmentation and failed to show improved outcomes in the graft augmentation group. 58 Recurrence of anterior vaginal wall prolapse (defined as POP-Q stage II or greater) was seen in 21% of the graft group and 29% of the control group. Logistic regression showed that supporting the anterior repair with SD/ IR-CFL did not reduce recurrent anterior prolapse (odds ratio 0.70); however, the presence of a transvaginal Cooper's ligament sling did reduce recurrence of anterior prolapse (odds ratio 0.105, P<0.001). In a multicenter follow-up of 132 patients who underwent anterior prolapse repair with SD/IR-CFL (Tutoplast, Mentor, Santa Barbara, CA), transvaginal sling that is anchored on the underside of the pubic bone (InFast, American Medical Systems, Inc, Minneapolis, MN) (CaPS procedure), Kobashi et al 56 reported a 87.1% complete cure rate (complete lack of cystocele) with 9.8% recurrent or de novo apical failure rate and 18% recurrence of stress incontinence at a mean follow-up of 12 months. Satisfaction or overall improvement was reported by 71% of patients. Groutz et al 55 used SD/ IR-CFL (Tutoplast, Mentor Corp, Santa Barbara, CA) for cystocele repair with and without SD/IR-CFL pubovaginal sling in 21 patients (19 patients had concomitant pubovaginal sling) and reported 100% cure for the anterior wall at 20 months with 11% of patients experiencing recurrent stress incontinence and 9% of patients developing a mild rectoenterocele at 4 to 6 months. Other allografts used include FD-CDA (Alloderm, LifeCell, Branchburg, NJ), which was demonstrated in a study to result in an 84% cure rate (no recurrence of any cystocele) in 19 patients at 28 months. 61 The authors also reported a 5% rate of infection requiring removal of graft and de novo urge incontinence.
Xenografts have also been employed to augment anterior repairs with some success. Gomelsky et al 63 retrospectively analyzed 70 patients who underwent vaginal paravaginal anterior repair with FD-PD (Intexen, AMS, Minnetonka, MN) sutured to bilateral arcus tendineous fascia pelvis with 65 of the patients undergoing concomitant pubovaginal sling (constructed from the above graft or ARF, based on patient preference) over a median follow-up interval of 24 months and found that 12.9% of patients had recurrent cystoceles (POP-Q stage II or greater) and 6.2% had recurrent stress urinary incontinence with 5% of patients developing de novo urge incontinence. There were no cases of erosion or rejection; however, there was 1 case of superficial vaginal incision separation, which resolved with conservative management. Another study examined 36 patients who underwent anterior repair augmented with HMDI/IR-PD, Pelvicol (C.R. Bard, West Sussex, UK) and concomitant high uterosacral vaginal vault suspension with median follow-up period of 17 months, and found a cure rate of 50% (POP-Q stage I or less). 64 Additionally, the authors assessed the effects of incontinence and urogenital distress in these patients using validated condition specific questionnaires and found decreased symptoms and bother in patients after undergoing the surgery.
In addition to the above traditional routes of vaginal anterior repair and paravaginal repair, xenograft (HMDI/ IR-PD) (Pelvicol, CR Bard, Murray Hill, NJ) has also been employed to augment anterior repairs via a transobturator approach together with a sacrospinous ligament fixation. 61 In 27 women, the authors demonstrated a complete cure rate of 81% with a median follow-up of 14 months without any evidence of rejection or infection. One patient did develop persistent pain despite conservative management. The graft was subsequently removed with resolution of pain. Histologic analysis of the graft revealed ingrowth of fibroblasts and blood vessels without significant inflammation. Another analysis reported on a variant of the traditional anterior repair (4-defect repair) with and without augmentation with HMDI/IR-PD (Pelvicol, CR Bard, Murray Hill, NJ) and found no cystocele recurrence in the graft group compared with 6.9% recurrence in the repair only group. 62 
SYNTHETIC MESH
In regards to the use of absorbable mesh in anterior repairs, the data is conflicting (Table 8 ). Weber et al 65 randomized 109 patients to standard anterior colporrhaphy or standard procedure plus polyglactin 910 mesh or ultralateral anterior colporrhaphy with a median follow-up time of 2 years. Objective anatomic outcomes were similar among the groups with only 1 patient experiencing mesh erosion. Sand et al 66 randomized 161 women to anterior colporrhaphy with and without polyglactin 910 mesh and found that women who underwent mesh placement during anterior colporrhaphy were less likely to experience recurrent cystocele at 1 year (25% vs. 42%, P = 0.02). There were no mesh-related complications reported.
The data for nonabsorbable mesh are also conflicting. Studies are difficult to compare as each has distinct definitions for outcomes, success, and complications. Although most uncontrolled case series demonstrated high anatomic cure rates, they also reported high mesh erosion rates and had short follow-up periods. For example, Julian 32 reported a cure rate of 100% for 12 patients who underwent repeat anterior vaginal prolapse repair with Marlex mesh, The authors reported 87 consecutive women with anterior vaginal wall prolapse who underwent a transvaginal reconstructive procedure using polypropylene mesh with a median follow-up time of 24 months. They reported an objective success rate of 91.6% and a mesh erosion rate of 8.3%. This same group also reported 37 month follow-up with 63 women with objective success rate of 89.1%, mesh erosion rate of 9.1%, and mesh-related pain rate of 5.5%. 69 In 2 additional published studies since the year 2000, approximately 80 patients underwent placement of polypropylene mesh during anterior vaginal wall repair, with success ranging from 94% to 100% and erosion ranging from 0% to 13%. 71, 72 Although reported success rates are encouraging, most study follow-up is limited to 2 to 3 years.
Modifications are now made to mesh with hopes of improved outcomes. de Tayrac et al 70 report on 143 women who underwent placement of a low-weight polypropylene mesh coated with an absorbable film (Ugytex, Sofradim, France) in either the anterior or posterior compartment with a median 13-month follow-up. They reported 92.3% anatomic cure rate with recurrent cystocele being the most common failure (6.8%) and an erosion rate of 6.3%. Knowing long-term outcomes and complications is vital before advocating widespread use of any new technologies.
SUMMATION
Most of the evidence addressing any type of biologic or synthetic mesh augmentation in anterior repairs fails to demonstrate a benefit over traditional repairs. Although most of the data are retrospective and uncontrolled, there are 2 level I studies that specifically addressed absorbable synthetic mesh (polyglactin 910) in anterior repair and found conflicting results with 1 trial, suggesting that there is no additional benefit (Weber et al), 65 whereas the other analysis indicating a decreased recurrence rate in the mesh arm (Sand et al) . 66 The conflicting findings could be secondary to the stricter definition of cure used by the Weber study and the longer follow-up period.
POSTERIOR REPAIR
Presently, there are limited long-term data supporting the use of either biologic grafts or synthetic mesh in posterior repairs. There has also been a disinclination to place synthetic mesh in the posterior compartment owing to the risk of dyspareunia and mesh erosion. Therefore, there has been a move toward biologic grafts (Table 9 ).
BIOLOGIC GRAFT
Oster and Astrup 76 described using autologous dermis in posterior repairs with 100% anatomic cure with a mean follow-up of 30 months. Kohli and Miklos 77 reported a 93% cure rate (point Ap < -0.5) at 13 months in 30 patients who underwent site-specific defect posterior repair augmented with FD-CDA (AlloDerm, LifeCell, Branchburg, NJ). There was no evidence of erosions or any significant complications from placement of the CDA. Another series that specifically addressed the rates of extrusion with anterior and posterior repairs augmented with FD-CDA (AlloDerm, LifeCell, Branchburg, NJ) found an extrusion rate of 10% (3/29) in anterior repairs, 9% (4/45) in posterior repairs with resolution of the extrusions with vaginal estrogen cream with and without the addition of antibiotics. 82 Dell and O'Kelley 78 retrospectively assessed their series of 35 patients 12 months after site-specific defect posterior repairs augmented with porcine dermal acellular collagen matrix (HMDI/IR/ F-PD) (PelviSoft BioMesh, CR Bard, Murray Hill, NJ) and concluded that all patients had good anatomic outcomes with average postoperative Ap and Bp measurements of -2.3 and -2.5, respectively, without adverse sexual or bowel symptoms. There was no evidence of delayed healing or vaginal incisional separation, which the authors did previously experience with a different PD, HMDI/IR-PD (Pelvicol, CR Bard, Murray Hill, NJ) (15% of patients). The authors postulated that the delayed healing experienced with Pelvicol was secondary to a lack of native tissue ingrowth into the porcine dermal graft, whereas the fenestrations present in the HMDI/IR/ F-PD (PelviSoft BioMesh, CR Bard, Murray Hill, NJ) would allow for immediate tissue contact without any issues of delayed healing or vaginal incisional dehiscence. Interestingly, Altman et al 83 in their experience with using HMDI/IR-PD (Pelvicol, CR Bard, Murray Hill, NJ) for rectocele repair augmentation found no graft-related complications at 12 or 36 months. Furthermore, these authors also conducted a histologic analysis of graftnative tissue interface from 17 patients and found no significant adverse inflammatory reactions. In terms of anatomic outcome, at 12 and 36 months follow-up, the authors found recurrent rectoceles of POP-Q stage II or greater in 38% and 41% of patients, respectively. 79, 80 Functionally, they found that although there were significant decreases in postoperative symptoms of bowel dysfunction and difficulty in rectal emptying compared with preoperation, subjective cure of evacuation difficulties was confirmed by No graft-related complications less than 50% of subjects. However, they found no significant changes in preoperative and postoperative dyspareunia rates, coital frequency, or number of sexually active patients. They concluded that further evaluation is required before adoption of rectocele repair augmentation with PD into clinical practice. At our institution, we recently completed a trial comparing traditional posterior colporrhaphy and defect-specific repairs of posterior vaginal wall prolapse with and without EDC/IR-SIS (FortaGen, Organogenesis, Canton, MA) graft augmentation. 81 In terms of failure, defined as recurrent posterior prolapse of POP-Q stage II or greater, we found that after one year follow-up, subjects who received a site-specific repair with EDC/IR-SIS graft augmentation had a significantly greater anatomic failure rate (46%) than those who received a site-specific repair alone or a traditional posterior repair (22% and 14%, respectively). However, there were no significant differences in functional outcomes between the groups as measured by validated condition specific quality of life questionnaires. There were also no adverse graft-related events.
SYNTHETIC MESH
The use of mesh in apical and anterior vaginal reconstruction procedures is far more common compared with the use in reconstruction of the posterior compartment (Table 10) . Physicians have been hesitant to place mesh in the posterior compartment secondary to its proximity to the rectum and potential infectious issues with foreign body placement. Additionally, as traditional posterior repairs are associated with high success rates ranging from 76% to 90%, the need for graft or mesh augmentation is further questioned. Sand et al 66 randomized 132 patients with central enterocele and rectocele to traditional repair or repair with polyglactin 910 mesh 86 published a report of 26 women undergoing rectocele repair with sacrospinous ligament fixation attached to polypropylene mesh. At 2 years, the anatomic success rate was 92.3% and the mesh erosion rate was 12%. Mercer-Jones et al 87 prospectively followed patients undergoing rectocele repair with either Vipro II (vicryl and prolene mesh) or prolene mesh (permanent mesh). Ninetyone percent of patients noted symptomatic improvement overall, with 38% of patients in the Vipro II arm subjectively rating outcomes as excellent versus 21% in the prolene mesh group (P<0.05). Complication differences were not described.
SUMMATION
Most studies dealing with graft or mesh augmentation of posterior repair are retrospective or uncontrolled with the evidence suggesting that there is no additional benefit to implant augmentation. There is one level I study that addressed using biologic graft (EDC/IR-SIS) in site-specific posterior repair compared with site-specific repair alone and traditional repair alone and found higher anatomic failure rates with the graft augmentation group (Paraiso et al 81 ). There is also one level I study that examined using absorbable mesh (polyglactin 910) in traditional rectocele repair and found no difference in recurrence rates (Sand et al 66 ) . However, as this study was powered to detect enterocele failures (not rectocele failures) and as incidence of rectocele recurrence was low, any significant difference between the mesh and traditional repair groups may have been missed.
NEW TECHNOLOGY
Despite the paucity of data, there is increased adoption of tension-free vaginal mesh procedures involving procedural kits, which include disposable insertion needles, retrieval devices, and polypropylene mesh. Those available at the present time include Anterior, Posterior, and Total Prolift (Ethicon, Somerville, NJ), Apogee and Perigee (American Medical Systems, Minnetonka, MN), and Avaulta (CR BARD, MURRAY HILL, NJ). Although the Prolift system is a minimally invasive procedure for the correction of anterior, posterior, or total prolapse with polypropylene mesh, Apogee and Perigee are used for anterior or posterior prolapse and employ either polypropylene mesh or porcine dermal grafts. Avaulta is an anterior repair system that uses a monofilament polypropylene mesh coated with hydrophilic porcine collagen.
A detailed PubMed search reveals no outcome or complication data for any of these new systems. Current data available for these new technologies consists of abstracts. One abstract addressed 687 patients undergoing prolapse repair with Prolift who were studied retrospectively. Initial intraoperative complications including bladder and rectal injuries, and hemorrhage were quite rare (1.32%) as were short-term postoperative complications (2.49%). 88 The authors considered 94.7% of pelvic organ prolapse to be cured at 3.6 months, although this outcome was not defined. Granuloma and mesh erosion ranged from 0% to 13.3% between study centers. The authors then compared the data from all women who were under 50 years old in this group to the entire study group and determined that Prolift is safe in women under 50 years of age and no significant difference was noted in pelvic organ prolapse recurrence among groups. 89 Graft erosion was noted to be significantly higher in women under 50 years old who underwent simultaneous hysterectomy.
A multicenter prospective study was performed evaluating the Apogee System for apical and posterior wall support. Fifty-five women with Zto grade II (Baden-Walker, BW) pelvic prolapse underwent the reconstructive procedure and had a mean follow-up time of 10.2 weeks. 90 At the last visit, the average POP-Q ''C point'' was 8 cm, the BW enterocele grade was 0 in 96% of patients, and BW rectocele grade was 0 in 100% of patients. Mesh exposure with or without granulation tissue occurred in 8 patients (14.5%) and dyspareunia was reported by 4% of patients. In another multicenter prospective study addressing anatomic and functional outcomes of a low-weight polypropylene mesh coated with a hydrophilic porcine collagen film (Sofradim, Trevoux, France, distributed by Bard as Pelvitex) for prolapse surgery with a mean follow-up period of 13 months, the recurrence rate was 7% (9/132 patients) for cystoceles and 2.6% (2/76) for rectoceles. 70 The erosion rate was 6.3% with a 12.8% de novo dyspareunia rate. Functional outcomes after surgery were improved as evidenced by significant decreases in validated Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire scores. Clearly additional data concerning long-term outcomes are needed before advocating widespread adoption of these systems.
Conclusions
There are few randomized controlled studies comparing graft or mesh augmentation techniques versus traditional repairs for apical, anterior, and/or posterior vaginal wall prolapse with most of the findings derived from retrospective or uncontrolled trials. Most of the evidence would suggest that augmentation with biologic graft or synthetic mesh does not result in increased anatomic cure rates and may even lead to higher recurrence rates. The only exception is that in abdominal sacral colpopexy procedures, the data do support using a synthetic mesh (polypropylene) to correct apical prolapse. As most anterior and posterior repair studies did not specifically target patients with recurrent prolapse or address the inherent tissue deficiencies of the patients, the greatest potential of using grafts or meshes may be in augmentation of deficient or weak endopelvic fascia and vaginal fibromuscular connective tissue.
There is no ideal biologic graft or synthetic mesh. New procedures should be evaluated prospectively, ideally with controlled trials. Random introduction of new materials may be unethical and potentially crippling. Cure rates associated with mesh or graft must be equal or better than cure associated with use of autologous tissue. Materials of the future will be impregnated with antibiotics and/or growth factors resulting in local control of tissue regeneration. Gene therapy will also likely play a role in future management of prolapse. The aim of using any implant in urogynecology and reconstructive pelvic surgery is to result in repairs that are safe, effective, and durable.
